Article
Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
Cancer research - 1 Feb 2014
Pishas Kathleen I, Neuhaus Susan J, Clayer Mark T, Schreiber Andreas W, Lawrence David M, Perugini Michelle, Whitfield Robert J, Farshid Gelareh, Manavis Jim, Chryssidis Steve, Mayo Bronwen J, Haycox Rebecca C, Ho Kristen, Brown Michael P, D'Andrea Richard J, Evdokiou Andreas, Thomas David M, Desai Jayesh, Callen David F, Neilsen Paul M
Abstract excerpt
Nutlin-3a is a small-molecule antagonist of p53/MDM2 that is being explored as a treatment for sarcoma. In this study, we examined the molecular mechanisms underlying the sensitivity of sarcomas to Nutlin-3a. In an ex vivo tissue explant system, we found that TP53 pathway alterations (TP53 status, MDM2/MDM4 genomic amplification/mRNA overexpression, MDM2 SNP309, and TP53 SNP72) did not confer apoptotic or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.